1344 N17350 combines selective cancer killing with adaptive immune activation to eradicate tumors

• Christine Lee,
• Nicole Grigaitis,
• Nicole Martinez,
• Maria Fumagalli,
• Chang Cui,
• Ravindra Gujar,
• Arezoo Arjmand,
• Catherine Reardon,
• Kelly Schoenfelt,
• Sonia Feau,
• Lev Becker

Affiliations

Christine Lee

Office of the Commissioner, Office of Minority Health and Health Equity, US Food and Drug Administration, Silver Spring, Maryland, USA

Nicole Grigaitis

OncoMyx Therapeutics, Phoenix, AZ, United States

Nicole Martinez

Center for Biomedical Ethics, Stanford University School of Medicine, Stanford, California, USA

Maria Fumagalli

Hibercell, Inc., Roseville, MN, United States

Chang Cui

1Onchilles Pharma, San Diego, CA, USA

Ravindra Gujar

1Onchilles Pharma, San Diego, CA, USA

Arezoo Arjmand

1Onchilles Pharma, San Diego, CA, USA

Catherine Reardon

2University of Chicago, Chicago, IL, USA

Kelly Schoenfelt

2University of Chicago, Chicago, IL, USA

Sonia Feau

1Onchilles Pharma, San Diego, CA, USA

Lev Becker

1Onchilles Pharma, San Diego, CA, USA